|Bid||20.16 x 0|
|Ask||20.19 x 0|
|Day's Range||19.15 - 20.27|
|52 Week Range||7.33 - 32.95|
|Beta (3Y Monthly)||4.95|
|PE Ratio (TTM)||36.35|
|Earnings Date||Aug 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.07|
Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) appears to be a worthy contender to Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB). Cronos has to match the success of Aurora Cannabis to prove that it is the better investment.
On Thursday, Bank of America downgraded Aurora Cannabis stock (ACB) to “neutral” from its previous “buy” rating. Here's why.
Aurora Cannabis Inc. has been downgraded by Bank of America Merrill Lynch, citing concern over the company’s cash burn and pending debt payments.
Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) seems very keen on disrupting the cannabis industry before Canopy Growth (TSX:WEED)(NYSE:CGC) enjoys leadership benefits.
In terms of sheer size, there is not a bigger market opportunity for cannabis than the United States. While estimates for a mature market in Canada range from $5 to $10 billion in annual sales, the U.S. market is expected to hit $22 billion in revenues by 2022, as per the 2018 edition of the […]
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today announced that it has entered into an agreement to acquire an 84,000 square foot GMP compliant fermentation and manufacturing facility in Winnipeg, Canada from Apotex Fermentation Inc. (“AFI”). As previously announced, Cronos Group has entered into a partnership with Ginkgo Bioworks, Inc. (“Ginkgo”) to produce cultured cannabinoids.